Robert Brady is a Psychiatry physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1430 Olive St
Suite 500
Saint Louis, MO 631032303
Telephone
314-206-3724Registry record last updated 8 Jul 2007.
Clinical trials
- Effects of Pregnancy-Specific Anxiety on Placental Inflammatory and Oxidative Stress Response and Birth Outcomes
Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine
- Hybrid Trial of Brief Cognitive-Behavioral Therapy for Health Anxiety in Primary Care
Sponsor: Dartmouth-Hitchcock Medical Center
- Mobile Apps for the Treatment of Depression
Sponsor: Central Arkansas Veterans Healthcare System
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Supernus Pharmaceuticals, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
97.4%Atypical Antipsychotic22%Aripiprazole35%Quetiapine Fumarate22%Risperidone9%Clozapine9%Olanzapine8%Paliperidone Er8%Quetiapine Fumarate Er7%Abilify Maintena5%Part D<11 patientsSSRI20%Escitalopram Oxalate22%Trazodone Hcl21%Fluoxetine Hcl17%Sertraline Hcl17%Lexapro9%Citalopram Hbr8%Paroxetine Hcl5%Part D<11 patients+ 17 more classes in this area
Cardiovascular
2.6%Central alpha-2 Adrenergic Agonist2.6%Guanfacine Hcl Er61%Clonidine Hcl39%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”